L22 Diversity Among Allergic March Trajectories
Children's Hospital of Philadelphia, Philadelphia, PA. RATIONALE: The allergic march describes the natural history of allergic manifestations as they develop during childhood. On a population level, the march begins with atopic dermatitis (AD), and is followed by IgEmediated food allergy (FA) and the respiratory allergies (RA; asthma and allergic rhinitis). However, the extent to which individuals follow this population-level disease development profile is not well understood. METHODS: Utilizing a primary care birth cohort of 130,457 children (entered age <1-year, followed > _24-months), we examined the disease development profiles of the major allergic manifestations (AD, FA, and RA) within individual children with more than one allergic manifestation. RESULTS: We found that the majority of children in our cohort progressed from AD to RA, without intermediate FA (42%, of whom 31% developed asthma only, 35% developed AR only, and 34% developed both). The second most common allergic trajectory was FA to RA, without preceding AD (21%, of whom 37% developed asthma only, 36% developed AR only, and 27% developed both). The third most common allergic trajectory was AD to FA to RA (9%, of whom 24% developed asthma only, 28% developed AR only, and 48% developed both). CONCLUSIONS: Our findings support the existence of multiple developmental trajectories within the allergic march. Future study of these patient cohorts is critical to improving our understanding of the relationship between the allergic manifestations.
L23
The 2 Vanderbilt University, Nashville, TN. RATIONALE: Although less than 4% test positive on formal drug allergy evaluation only 50-85% are functionally ''de-labeled'' and will take the medication in the future. The behavioral factors that influence patient perception of drug allergy testing are currently poorly understood. METHODS: We conducted a prospective, observational survey-based study in an outpatient drug allergy clinic to assess patient perception and anxiety at different timepoints during drug allergy evaluation. Anxiety was assessed before and after each drug allergy test and 1 week following testing using a validated anxiety tool. Data from 25 of a targeted sample size of 100 was analyzed using nonparametric Wilcoxon matched-pairs signed-rank to evaluate intrapersonal anxiety changes at different timepoints. RESULTS: Nearly all (92%) agreed evaluation of their drug allergy status was important, only 72% would feel comfortable if told they did not have an allergy. Immediately following negative testing, 64% felt confident with the negative evaluation and 56% affirmed comfort in taking the drug. Reported anxiety specific to drug allergy, skin testing, and ingestion challenge decreased during the single visit evaluation, but after one week 29% and 41% reported increased anxiety specific to drug allergy and ingestion challenge, respectively, with 24% losing confidence in the negative evaluation. CONCLUSIONS: Although patient anxiety transiently diminished during drug allergy assessment a significant proportion of patients did not feel comfortable with a negative evaluation and the advice that the drug may be taken safely in the future. Targeted follow-up communication and behavioral interventions appear necessary to improve the sustained effectiveness of drug allergy assessment.
